There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Omeros Corp (NASDAQ: OMER), Savara Inc (NASDAQ: SVRA) and Supernus Pharmaceuticals (NASDAQ: SUPN) with bullish sentiments.
Omeros Corp (NASDAQ: OMER)
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Omeros Corp (NASDAQ: OMER) today and set a price target of $34. The company’s shares closed yesterday at $19.84.
Selvaraju wrote:
“We remind investors that, only last year, Omeros announced that it had settled litigation directed to an ANDA filing by Par Sterile Products, LLC and Par Pharmaceutical, Inc. As in the settlement with Par, this agreement with Lupin includes Lupin’s acknowledgment and confirmation of the validity of all asserted patents for OMIDRIA as well as overall terms and market entry date similar to those set forth in the Par agreement—we note that Par has agreed not to launch a generic version of OMIDRIA until the earliest. The expiration date of the last-to-expire of Omeros’ asserted patents for OMIDRIA is October 23, 2033. The litigation against Lupin began in 2017 after Omeros received a Paragraph IV certification from Lupin in connection with Lupin’s filing of an ANDA seeking the FDA’s approval to market a generic version of OMIDRIA.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -3.5% and a 37.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on Omeros Corp is Moderate Buy and the average price target is $34.60, representing a 74.4% upside.
In a report issued on May 11, Maxim Group also maintained a Buy rating on the stock with a $25 price target.
See today’s analyst top recommended stocks >>
Savara Inc (NASDAQ: SVRA)
H.C. Wainwright analyst Andrew Fein initiated coverage with a Buy rating on Savara Inc (NASDAQ: SVRA) today and set a price target of $22. The company’s shares closed yesterday at $8.55.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 7.2% and a 50.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.
Savara Inc has an analyst consensus of Strong Buy, with a price target consensus of $22.33.
Supernus Pharmaceuticals (NASDAQ: SUPN)
In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on Supernus Pharmaceuticals (NASDAQ: SUPN), with a price target of $60. The company’s shares closed yesterday at $55.65, close to its 52-week high of $59.05.
According to TipRanks.com, Samimy is a 4-star analyst with an average return of 10.9% and a 53.2% success rate. Samimy covers the Healthcare sector, focusing on stocks such as Clearside Biomedical, Cara Therapeutics, and Mallinckrodt.
Currently, the analyst consensus on Supernus Pharmaceuticals is Strong Buy and the average price target is $55.80, representing a 0.3% upside.
In a report issued on May 14, B.Riley FBR also reiterated a Buy rating on the stock with a $68 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
